UT-ICON-HEALTH-&-FITNESS
11.1.2021 12:02:50 CET | Business Wire | Press release
iFit, a global leader in interactive connected fitness technology, today announced the upcoming release of iFit ActivePulse automatic heart rate training. iFit’s cutting edge technology uses complex algorithms so an iFit subscriber’s heart rate controls the treadmill in real time, automatically adjusting the speed and incline to maintain the optimal heart rate zone.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210111005174/en/
iFit’s game-changing innovation removes the guesswork from heart rate training, by allowing a member’s heart rate to automatically scale and tailor iFit’s vast library of workouts to their individual fitness levels and goals. iFit has applied for patent protection on ActivePulse, which will be available on all iFit-controlled NordicTrack® , ProForm® and Freemotion® treadmills.
Until now, the benefits of heart rate training have hinged on how well a person is able to manually monitor and adjust their effort in order to remain in a particular heart rate zone. In contrast, iFit ActivePulse creates a real-time feedback loop between a user’s measured heart rate and the treadmill’s speed and incline.
iFit ActivePulse heart rate training keeps the user in their optimal zone, while enabling them to accomplish their fitness goals by targeting different heart rate zones.
“ActivePulse lets each iFit customer's heart rate personalize their treadmill workout without the complicated calculations and constant manual adjustments that have long been associated with heart rate training,” said Mark Watterson, President of iFit. “ActivePulse provides a workout that is catered not just to a member; it is catered to that member based on how their heart rate is functioning during the workout.”
Daily variables such as hydration, sleep, and stress have a direct impact on heart rate, therefore the effectiveness of a given workout can vary from one day to the next based on heart rate performance. iFit ActivePulse scales and tailors the intensity of any iFit program to optimize the workout based on their heart rate at that moment—even incorporating advanced algorithms to gradually “learn” their unique behavioral patterns over time.
Heart rate training—the concept of exercising within predetermined ranges (or “zones”) of a user’s maximum heart rate to achieve specific fitness goals—has been used by elite athletes and coaches around the world for more than 30 years. With various heart rate zones corresponding to fitness goals like building endurance, and promoting recovery, heart rate training is widely accepted as the most intelligent way to achieve consistent and measurable progress towards specific fitness goals.
iFit ActivePulse is compatible with leading Bluetooth® heart rate monitors with broadcast functionality, including the iFit SmartBeat™ forearm heart rate monitor, as well as third-party devices from brands including Polar®, Garmin®, Wahoo® and WHOOP®.
Included with all iFit memberships, ActivePulse will be available on all iFit-enabled NordicTrack, ProForm and Freemotion treadmills via an automatic iFit software update in January 2021. The feature will become available for stationary bikes, rowers, and ellipticals from NordicTrack, ProForm and Freemotion soon thereafter.
About iFit
iFit is the patented connected fitness platform that powers NordicTrack, ProForm and Freemotion equipment. ICON, the creator and owner of iFit, pioneered interactive fitness and was issued its first of many patents for its training technology in the early 2000s. Founded with the belief that the majority of consumers would benefit from an interactive, personal training experience at home, iFit’s trainer-led, streaming workouts are now trusted by millions of consumers around the world.
iFit offers workout options for every fitness level and interest—from bodyweight training, boxing, HIIT, yoga, Pilates and more—to connected fitness workouts on NordicTrack home equipment. Patented interactive technology allows iFit Trainers to create workouts for iFit members that automatically adjust the member’s incline, decline, speed and resistance in sync with iFit’s streaming workouts. iFit interactive content is available on NordicTrack, ProForm and Freemotion treadmills, stationary bikes, rowers, ellipticals, strength machines and the iFit app.
ICON Health & Fitness, Inc. is a global health and fitness leader and owner of iFit, NordicTrack, ProForm, Freemotion and other fitness brands. Based in Logan, Utah, the 43-year old company has a multi-decade heritage of innovation and quality. ICON currently holds more than 330 patents, with more than 80 pending, and its products are sold in 116 countries. iFit workouts are streamed in English, Spanish, French and Mandarin Chinese, with more languages planned for 2021.
Join the discussion @iFit , @NordicTrack and @ProForm
View source version on businesswire.com: https://www.businesswire.com/news/home/20210111005174/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom